Residual Disease in Spondyloarthritis: What's Being Missed by DMARDs?

(MedPage Today) -- In spondyloarthritis (SpA), the wealth of biologic and disease-modifying anti-rheumatic drug (DMARD) options still leaves some patients unsatisfied with their treatment outcomes, most likely due to residual disease. This year...